Novira Therapeutics gets $11m first tranche of Series A for capsid-targeting antivirals
This article was originally published in Scrip
Executive Summary
Novira Therapeutics, a small Radnor, Pennsylvania-based antiviral drug discovery firm with oral capsid-targeting medicines in development for large indications, has raised the first $11 million of a two-tranche, $23 million Series A financing round to advance small molecules for the treatment of hepatitis B virus (HBV) and HIV into the clinic.